Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals

D. A. Goodwin, C. F. Meares, G. F. David, M. McTigue, M. J. McCall, J. M. Frincke, M. R. Stone, R. M. Bartholomew, J. P. Leung

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


We have prepared monoclonal antibodies (MoAbs) with the specific ability to bind metal chelates such as 111In benzyl EDTA. One, 10, 50 and 100 μg MoAb CHA255 K(b) = 4 x 10E9 was complexed with 111In BLEDTA II, BLEDTA IV, and benzyl EDTA and injected i.v. in Balb/c mice with KHJJ tumor. The biological half-life by whole body counting was profoundly altered for all three compounds; from minutes to hours with 10 μg; to days with 100 μg. Tumor uptake increased 50 fold at 24 h with increasing MoAb but satisfactory tumor concentrations (3% per g) and tumor/blood ratios (1.8:1) were obtained with an amount equivalent to 7 mg for a human. Blood level and whole body activity were decreased 30-50% within 3 h or i.v. injection of a 'flushing' dose of unlabeled indium benzyl EDTA, increasing tumor/blood ratios to 50:1.

Original languageEnglish (US)
Pages (from-to)383-391
Number of pages9
JournalNuclear Medicine and Biology
Issue number4
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals'. Together they form a unique fingerprint.

Cite this